Orexo sues Actavis and Teva over narcotic dependency treatment
Pharmaceutical company Orexo has filed a complaint against Actavis Elizabeth and Teva Pharmaceuticals for infringing its patents covering Zubsolv (buprenorphine and naloxone).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
11 September 2018 The US Court of Appeals for the Federal Circuit yesterday revived a patent infringement lawsuit against Teva Pharmaceuticals, in a win for Sweden-based Orexo.
11 September 2018 The US Court of Appeals for the Federal Circuit yesterday revived a patent infringement lawsuit against Teva Pharmaceuticals, in a win for Sweden-based Orexo.
11 September 2018 The US Court of Appeals for the Federal Circuit yesterday revived a patent infringement lawsuit against Teva Pharmaceuticals, in a win for Sweden-based Orexo.